Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease
Alterations in the activity of tryptophan 2,3-dioxygenase (TDO) cause imbalances in the levels of serotonin and other neuroactive metabolites which can contribute to motor, psychiatric, gastrointestinal, and other dysfunctions often seen in Parkinson's disease (PD). TDO is a key enzyme of trypt...
Elmentve itt :
| Szerzők: |
Boros Fanni Annamária Vécsei László |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2021
|
| Sorozat: | EXPERT OPINION ON THERAPEUTIC TARGETS
25 No. 10 |
| Tárgyszavak: | |
| doi: | 10.1080/14728222.2021.1999928 |
| mtmt: | 32473786 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/25742 |
Hasonló tételek
-
Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease
Szerző: Boros Fanni Annamária, et al.
Megjelent: (2019) -
The genetic background of Parkinson's disease and novel therapeutic targets
Szerző: Salamon András, et al.
Megjelent: (2022) -
Novel therapeutic strategies in Parkinson's disease
Szerző: Klivényi Péter, et al.
Megjelent: (2010) -
Altered tryptophan metabolism in Parkinson's disease A possible novel therapeutic approach /
Szerző: Szabó Nikoletta, et al.
Megjelent: (2011) -
Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase 1 Influenced the Age Onset of Parkinson's Disease
Szerző: Török Nóra, et al.
Megjelent: (2022)